Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT03118466 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03118466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03118466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 25, 2017
Completion date
August 18, 2021
Enrollment
41 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

aml